Kisoji Biotechnology
- | Biotech or pharma, therapeutic R&D
KisoJi has created the world’s largest single-domain antibody database—over 25 million validated antibodies—to power its proprietary AI platform.
This unmatched dataset enables KisoJi to pioneer transformative therapeutic breakthroughs using its antibody platform, which includes:
- KisoMouse: A multi-species camelid transgenic mouse generating highly drug-like biological antibodies across all target epitopes.
- KisoSeek: AI tools for paratope mapping and structural antibody search, enabling real-time, precise analysis of antibody repertoires.
- KisoBody: A cutting-edge platform for generating multispecific antibodies with unprecedented yield and multiple mechanisms of action.
Through its platform, KisoJi has discovered its lead program, KJ-103, a first in class naked TROP2 antibody that will enter the clinic in 2026.
KisoJi is currently raising a financing round to scale its AI platform and expand its pipeline of innovative antibody medicines addressing the world’s most devastating diseases.
Address
MontrealQue
Canada
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}